Evolocumab mechanism to reduce LDL cholesterol (WP3408)
Homo sapiens
Evolocumab (Repatha) is an injectable monoclonal antibody that effectively reduces LDL-Cholesterol levels. A limited quantity of LDL-Cholesterol is extracted from circulative blood when PCSK9-bound LDLR is degraded upon internalization in Liver cells. Evolocumab competitively bind PCSK9 away from LDLR complexes, which allows LDLR to be recycled, returning to the surface and clearing additional molecules of LDL-Cholesterol.
Authors
Alex Pico , Egon Willighagen , Susan Coort , Denise Slenter , Eric Weitz , Marvin Martens , Martina Summer-Kutmon , and Lars WillighagenActivity
Discuss this pathway
Check for ongoing discussions or start your own.
Cited By
Are you planning to include this pathway in your next publication? See How to Cite and add a link here to your paper once it's online.
Organisms
Homo sapiensCommunities
DiseasesAnnotations
Pathway Ontology
altered cholesterol biosynthetic pathway altered cholesterol transport pathway drug pathwayCell Type Ontology
hepatocyteLabel | Type | Compact Identifier | Comment |
---|---|---|---|
LDL-Cholesterol | Metabolite | chebi:47774 | |
Evolocumab | Metabolite | wikidata:Q15623825 | |
LDL-Cholesterol | Metabolite | chebi:47774 | |
LDL-Cholesterol | Metabolite | chebi:47774 | |
LDL-Cholesterol | Metabolite | chebi:47774 | |
LDL-Cholesterol | Metabolite | chebi:47774 | |
PCSK9 | GeneProduct | ensembl:ENSG00000169174 | |
LDLR | GeneProduct | ensembl:ENSG00000130164 | |
PCSK9 | GeneProduct | ensembl:ENSG00000169174 | |
LDLR | GeneProduct | ensembl:ENSG00000130164 | |
PCSK9 | GeneProduct | ensembl:ENSG00000169174 | |
LDLR | GeneProduct | ensembl:ENSG00000130164 | |
LDLR | GeneProduct | ensembl:ENSG00000130164 | |
LDLR | GeneProduct | ensembl:ENSG00000130164 |
References
- PCSK9 inhibitors: the next cholesterol-lowering blockbusters? The Pharmaceutical Journal [Internet]. 2015; Available from: http://dx.doi.org/10.1211/PJ.2015.20068181 DOI